Richard G Stock

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2770344/publications.pdf

Version: 2024-02-01

116 papers	5,617 citations	71102 41 h-index	79698 73 g-index
116 all docs	116 docs citations	116 times ranked	2551 citing authors

#	Article	IF	Citations
1	American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy, 2012, 11, 6-19.	0.5	399
2	Comparative analysis of prostateâ€specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU International, 2012, 109, 22-29.	2.5	391
3	IDENTIFICATION OF PATIENTS AT INCREASED RISK FOR PROLONGED URINARY RETENTION FOLLOWING RADIOACTIVE SEED IMPLANTATION OF THE PROSTATE. Journal of Urology, 1998, 160, 1379-1382.	0.4	258
4	A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantation. International Journal of Radiation Oncology Biology Physics, 1995, 32, 219-225.	0.8	240
5	Biologically effective dose values for prostate brachytherapy: Effects on PSA failure and posttreatment biopsy results. International Journal of Radiation Oncology Biology Physics, 2006, 64, 527-533.	0.8	221
6	Defining the risk of developing Grade 2 proctitis following 125I prostate brachytherapy using a rectal doseâ€“volume histogram analysis. International Journal of Radiation Oncology Biology Physics, 2001, 50, 335-341.	0.8	211
7	LAPAROSCOPIC PELVIC LYMPH NODE DISSECTION FOR PROSTATE CANCER: COMPARISON OF THE EXTENDED AND MODIFIED TECHNIQUES. Journal of Urology, 1997, 158, 1891-1894.	0.4	194
8	PENILE ERECTILE FUNCTION AFTER PERMANENT RADIOACTIVE SEED IMPLANTATION FOR TREATMENT OF PROSTATE CANCER. Journal of Urology, 2001, 165, 436-439.	0.4	189
9	Long-Term Outcome and Toxicity of Salvage Brachytherapy for Local Failure After Initial Radiotherapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2010, 77, 1338-1344.	0.8	142
10	Multicenter Analysis of Effect of High Biologic Effective Dose on Biochemical Failure and Survival Outcomes in Patients With Gleason Score 7â€“10 Prostate Cancer Treated With Permanent Prostate Brachytherapy. International Journal of Radiation Oncology Biology Physics, 2009, 73, 341-346.	0.8	126
11	Prostate-specific antigen bounce after prostate seed implantation for localized prostate cancer: descriptions and implications. International Journal of Radiation Oncology Biology Physics, 2003, 56, 448-453.	0.8	125
12	Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation. International Journal of Radiation Oncology Biology Physics, 2002, 52, 444-452.	0.8	123
13	Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma. , 1996, 77, 2386-2392.		121
14	Sexual potency following interactive ultrasound-guided brachytherapy for prostate cancer. International Journal of Radiation Oncology Biology Physics, 1996, 35, 267-272.	0.8	118
15	Long-Term Urinary, Sexual, and Rectal Morbidity in Patients Treated with Iodine-125 Prostate Brachytherapy Followed Up for a Minimum of 5 Years. Urology, 2007, 69, 338-342.	1.0	113
16	Acute urinary morbidity following I-125 interstitial implantation of the prostate gland. Radiation Oncology Investigations, 1998, 6, 135-141.	0.9	104
17	Postimplant dosimetry for 125I prostate implants: definitions and factors affecting outcome. International Journal of Radiation Oncology Biology Physics, 2000, 48, 899-906.	0.8	102
18	Customized Dose Prescription for Permanent Prostate Brachytherapy: Insights From a Multicenter Analysis of Dosimetry Outcomes. International Journal of Radiation Oncology Biology Physics, 2007, 69, 1472-1477.	0.8	92

#	Article	IF	Citations
19	PROSTATE BRACHYTHERAPY: TREATMENT STRATEGIES. Journal of Urology, 1999, 162, 421-426.	0.4	91
20	Combined modality treatment in the management of high-risk prostate cancer. International Journal of Radiation Oncology Biology Physics, 2004, 59, 1352-1359.	0.8	91
21	Local Control Following Permanent Prostate Brachytherapy: Effect of High Biologically Effective Dose on Biopsy Results and Oncologic Outcomes. International Journal of Radiation Oncology Biology Physics, 2010, 76, 355-360.	0.8	90
22	Importance of Post-Implant Dosimetry in Permanent Prostate Brachytherapy. European Urology, 2002, 41, 434-439.	1.9	77
23	Comparison of intraoperative dosimetric implant representation with postimplant dosimetry in patients receiving prostate brachytherapy. Brachytherapy, 2003, 2, 17-25.	0.5	72
24	Disease-specific survival following the brachytherapy management of prostate cancer. International Journal of Radiation Oncology Biology Physics, 2006, 64, 810-816.	0.8	72
25	Meta-analysis of Genome Wide Association Studies Identifies Genetic Markers of Late Toxicity Following Radiotherapy for Prostate Cancer. EBioMedicine, 2016, 10, 150-163.	6.1	69
26	American Brachytherapy Society Task Group Report: Combination of brachytherapy and external beam radiation for high-risk prostate cancer. Brachytherapy, 2017, 16, 1-12.	0.5	69
27	Indications for Seminal Vesicle Biopsy and Laparoscopic Pelvic Lymph Node Dissection in Men With Localized Carcinoma of Prostate. Journal of Urology, 1995, 154, 1392-1396.	0.4	67
28	Influence of Pretreatment and Treatment Factors on Intermediate to Long-Term Outcome After Prostate Brachytherapy. Journal of Urology, 2011, 185, 495-500.	0.4	64
29	125I Monotherapy Using D90 Implant Doses of 180 Gy or Greater. International Journal of Radiation Oncology Biology Physics, 2008, 70, 96-101.	0.8	60
30	Radiation Dose Predicts for Biochemical Control in Intermediate-Risk Prostate Cancer Patients Treated With Low-Dose-Rate Brachytherapy. International Journal of Radiation Oncology Biology Physics, 2009, 75, 16-22.	0.8	60
31	Outcomes for patients with highâ€grade prostate cancer treated with a combination of brachytherapy, external beam radiotherapy and hormonal therapy. BJU International, 2009, 104, 1631-1636.	2.5	60
32	What is the optimal dose for 125I prostate implants? A dose-response analysis of biochemical control, posttreatment prostate biopsies, and long-term urinary symptoms. Brachytherapy, 2002, 1, 83-89.	0.5	59
33	Postoperative Nomogram Predicting the 9-Year Probability of Prostate Cancer Recurrence After Permanent Prostate Brachytherapy Using Radiation Dose as a Prognostic Variable. International Journal of Radiation Oncology Biology Physics, 2010, 76, 1061-1065.	0.8	59
34	A 2-Stage Genome-Wide Association Study to Identify Single Nucleotide Polymorphisms Associated With Development of Erectile Dysfunction Following Radiation Therapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2013, 85, e21-e28.	0.8	59
35	Prostate brachytherapy:Improvements in prostate volume measurements and dose distribution using interactive ultrasound guided implantation and three-dimensional dosimetry. Radiation Oncology Investigations, 1995, 3, 185-195.	0.9	55
36	The effect of prognostic factors on therapeutic outcome following transperineal prostate brachytherapy. , 1997, 13, 454-460.		53

#	Article	IF	Citations
37	Laparoscopic Pelvic Lymph Node Dissection Combined with Real-time Interactive Transrectal Ultrasound Guided Transperineal Radioactive Seed Implantation of the Prostate. Journal of Urology, 1995, 153, 1555-1560.	0.4	52
38	A biochemical definition of cure after brachytherapy for prostate cancer. Radiotherapy and Oncology, 2020, 149, 64-69.	0.6	48
39	Seminal vesicle biopsy: Accuracy and implications for staging of prostate cancer. Urology, 1996, 48, 757-761.	1.0	45
40	The effect of disease and treatment-related factors on biopsy results after prostate brachytherapy. Cancer, 2000, 89, 1829-1834.	4.1	44
41	Changing the patterns of failure for high-risk prostate cancer patients by optimizing local control. International Journal of Radiation Oncology Biology Physics, 2006, 66, 389-394.	0.8	43
42	Prognostic Significance of 5-Year PSA Value for Predicting Prostate Cancer Recurrence After Brachytherapy Alone and Combined With Hormonal Therapy and/or External Beam Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2009, 74, 753-758.	0.8	42
43	Treatment outcomes and morbidity following definitive brachytherapy with or without external beam radiation for the treatment of localized prostate cancer: 20-Year experience at Mount Sinai Medical Center. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 38.e1-38.e7.	1.6	42
44	Brachytherapy for the Treatment of Prostate Cancer. Cancer Journal (Sudbury, Mass), 2007, 13, 302-312.	2.0	38
45	PSA Nadir of <0.5 ng/mL Following Brachytherapy for Early-Stage Prostate Adenocarcinoma is Associated With Freedom From Prostate-Specific Antigen Failure. International Journal of Radiation Oncology Biology Physics, 2012, 83, 600-607.	0.8	36
46	Impact of Hormonal Therapy on Intermediate Risk Prostate Cancer Treated With Combination Brachytherapy and External Beam Irradiation. Journal of Urology, 2010, 183, 546-551.	0.4	33
47	Longâ€term potency preservation following brachytherapy for prostate cancer. BJU International, 2012, 110, 221-225.	2.5	32
48	Long-term Outcomes and Toxicity in Patients Treated With Brachytherapy for Prostate Adenocarcinoma Younger Than 60 Years of Age at Treatment With Minimum 10 Years of Follow-up. Urology, 2013, 81, 364-369.	1.0	31
49	Factors Influencing Urinary Symptoms 10 Years After Permanent Prostate Seed Implantation. Journal of Urology, 2012, 187, 117-123.	0.4	30
50	15-Year Cause Specific and All-Cause Survival Following Brachytherapy for Prostate Cancer: Negative Impact of Long-Term Hormonal Therapy. Journal of Urology, 2014, 192, 754-759.	0.4	27
51	Lowâ€doseâ€rate brachytherapy for prostate cancer: outcomes at >10 years of followâ€up. BJU International, 2018, 121, 781-790.	2.5	26
52	Low dose rate brachytherapy for primary treatment of localized prostate cancer: A systemic review and executive summary of an evidence-based consensus statement. Brachytherapy, 2021, 20, 1114-1129.	0.5	26
53	Does prostate brachytherapy treat the seminal vesicles? A doseâ€“volume histogram analysis of seminal vesicles in patients undergoing combined PD-103 prostate implantation and external beam irradiation. International Journal of Radiation Oncology Biology Physics, 1999, 45, 385-389.	0.8	24
54	Screening breast cancer patients forATM mutations and polymorphisms by using denaturing high-performance liquid chromatography. Environmental and Molecular Mutagenesis, 2001, 38, 200-208.	2.2	24

#	Article	IF	Citations
55	Assessment of postbrachytherapy sexual function: A comparison of the IIEF-5 and the MSEFS. Brachytherapy, 2007, 6, 26-33.	0.5	21
56	Outcomes for patients with extraprostatic prostate cancer treated with trimodality therapy, including brachytherapy, external beam radiotherapy, and hormone therapy. Brachytherapy, 2011, 10, 261-268.	0.5	21
57	The Effect of Brachytherapy, External Beam Irradiation and Hormonal Therapy on Prostate Volume. Journal of Urology, 2007, 177, 925-928.	0.4	20
58	Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3502 patients. Radiotherapy and Oncology, 2020, 151, 26-32.	0.6	19
59	PSA kinetics following I-125 radioactive seed implantation in the treatment of T1-T2 prostate cancer. Radiation Oncology Investigations, 1999, 7, 30-35.	0.9	18
60	Update on Prostate Brachytherapy: Long-term Outcomes and Treatment-related Morbidity. Current Urology Reports, 2011, 12, 237-242.	2.2	18
61	Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer. JAMA Oncology, 2022, 8, e216871.	7.1	18
62	Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomographyâ€“Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer. JAMA Network Open, 2021, 4, e2138550.	5.9	18
63	Preliminary toxicity and prostate-specific antigen response of a Phase I/II trial of neoadjuvant hormonal therapy, 103Pd brachytherapy, and three-dimensional conformal external beam irradiation in the treatment of locally advanced prostate cancerâ€¢. Brachytherapy, 2002, 1, 2-10.	0.5	17
64	Distant and local recurrence in patients with biochemical failure after prostate brachytherapy. Brachytherapy, 2008, 7, 217-222.	0.5	17
65	Current Topics in the Treatment of Prostate Cancer with Low-Dose-Rate Brachytherapy. Urologic Clinics of North America, 2010, 37, 83-96.	1.8	17
66	The relative importance of hormonal therapy and biological effective dose in optimizing prostate brachytherapy treatment outcomes. BJU International, 2013, 112, E44-50.	2.5	15
67	Findings at Cystoscopy Performed for Cause After Prostate Brachytherapy. Urology, 2014, 83, 1350-1355.	1.0	15
68	A Deep Learning Approach Validates Genetic Risk Factors for Late Toxicity After Prostate Cancer Radiotherapy in a REQUITE Multi-National Cohort. Frontiers in Oncology, 2020, 10, 541281.	2.8	15
69	Estimated Costs Associated With Radiation Therapy for Positive Surgical Margins During Radical Prostatectomy. JAMA Network Open, 2020, 3, e201913.	5.9	15
70	Low-dose cranial boost in high-risk adult acute lymphoblastic leukemia patients undergoing bone marrow transplant. Practical Radiation Oncology, 2017, 7, 103-108.	2.1	14
71	Do high radiation doses in locally advanced prostate cancer patients treated with 103Pd implant plus external beam irradiation cause increased urinary, rectal, and sexual morbidity?. Brachytherapy, 2010, 9, 114-118.	0.5	13
72	Diagnosis and management of local recurrence after low-dose-rate brachytherapy. Brachytherapy, 2015, 14, 124-130.	0.5	12

#	Article	IF	Citations
73	Outcomes and toxicities in patients with intermediateâ€risk prostate cancer treated with brachytherapy alone or brachytherapy and supplemental external beam radiation therapy. BJU International, 2018, 121, 774-780.	2.5	12
74	Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features. JAMA Network Open, 2021, 4, e2115312.	5.9	12
75	Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer. European Urology, 2021, 80, 142-146.	1.9	12
76	Gleason 7 prostate cancer treated with lowâ€doseâ€rate brachytherapy: lack of impact of primary Gleason pattern on biochemical failure. BJU International, 2012, 110, 1257-1261.	2.5	11
77	Development of a method for generating SNP interaction-aware polygenic risk scores for radiotherapy toxicity. Radiotherapy and Oncology, 2021, 159, 241-248.	0.6	11
78	Counterpoint: There is a doseâ€“response relationship in the lowâ€“dose rate brachytherapy management of prostate cancer. Brachytherapy, 2010, 9, 293-296.	0.5	10
79	Use of angiotensin converting enzyme inhibitors is associated with reduced risk of late bladder toxicity following radiotherapy for prostate cancer. Radiotherapy and Oncology, 2022, 168, 75-82.	0.6	10
80	Predictors of Metastatic Disease After Prostate Brachytherapy. International Journal of Radiation Oncology Biology Physics, 2012, 83, 645-652.	0.8	9
81	Does dose matter? Editorial comments to Morris etÂal. Whole prostate D90 and V100: A doseâ€“response analysis of 2000 consecutive 125I monotherapy cases. Brachytherapy, 2014, 13, 42-43.	0.5	9
82	Salvage low dose rate brachytherapy for prostate cancer recurrence following definitive external beam radiation therapy. Radiotherapy and Oncology, 2021, 155, 42-47.	0.6	8
83	Long-term oncological and functional outcomes support use of low-dose-rate brachytherapy with or without external beam radiation in young men (â‰60Âyears) with localized prostate cancer. Brachytherapy, 2019, 18, 192-197.	0.5	7
84	Biopsy and implantation of the seminal vesicles. Brachytherapy, 2012, 11, 334-340.	0.5	6
85	Racial Disparities in Clinically Significant Prostate Cancer Treatment: The Potential Health Information Technology Offers. Journal of Oncology Practice, 2018, 14, e23-e33.	2.5	6
86	Durable disease control with local treatment for oligoprogression of metastatic solid tumors treated with immune checkpoint blockade. Cancer Treatment and Research Communications, 2020, 25, 100216.	1.7	6
87	The impact of a rectal hydrogel spacer on dosimetric and toxicity outcomes among patients undergoing combination therapy with external beam radiotherapy and low-dose-rate brachytherapy. Brachytherapy, 2021, 20, 296-301.	0.5	6
88	Radiopharmaceuticals for Bone Metastases. Seminars in Radiation Oncology, 2021, 31, 45-59.	2.2	6
89	Factors influencing longâ€term urinary symptoms after prostate brachytherapy. BJU International, 2018, 122, 831-836.	2.5	5
90	Long-term biochemical control and cause-specific survival in men with Gleason grade Group 4 and 5 prostate cancer treated with brachytherapy and external beam irradiation. Brachytherapy, 2020, 19, 275-281.	0.5	5

#	Article	IF	Citations
91	Radium-223 for Metastatic Castrate-Resistant Prostate Cancer. Practical Radiation Oncology, 2022, 12, 312-316.	2.1	5
92	Stage T3b prostate cancer diagnosed by seminal vesicle biopsy and treated with neoadjuvant hormone therapy, permanent brachytherapy and external beam radiotherapy. BJU International, 2019, 123, 277-283.	2.5	4
93	High-dose-rate versus low-dose-rate monotherapy in the treatment of localized prostate cancer: The case for low-dose-rate monotherapy. Brachytherapy, 2006, 5, 5-6.	0.5	3
94	Association of early PSA failure time with increased distant metastasis and decreased survival in prostate brachytherapy patients. Radiotherapy and Oncology, 2014, 110, 261-267.	0.6	2
95	The impact of timing of salvage hormonal therapy on survival after brachytherapy for prostate cancer. Brachytherapy, 2016, 15, 730-735.	0.5	2
96	Counterpoint: High-risk prostate cancer: The case for combination brachytherapy and external beam irradiation. Brachytherapy, 2008, 7, 280-282.	0.5	1
97	Permanent prostate brachytherapy is safe in men with severe baseline lower urinary tract symptoms. Brachytherapy, 2019, 18, 332-337.	0.5	1
98	I-125 or Pd-103 for brachytherapy boost in men with high-risk prostate cancer: A comparison of survival and morbidity outcomes. Brachytherapy, 2020, 19, 567-573.	0.5	1
99	Survey of Radiation Oncologists to Assess Interest and Potential Use of a Genetic Test Predicting Susceptibility for the Development of Toxicities After Prostate Cancer Radiation Therapy. Advances in Radiation Oncology, 2020, 5, 897-904.	1.2	1
100	Live implant dosimetry may be an effective replacement for postimplant computed tomography in localized prostate cancer patients receiving low dose rate brachytherapy. Brachytherapy, 2021, 20, 873-882.	0.5	1
101	Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma. Cancer, 1996, 77, 2386-2392.	4.1	1
102	PRINT: Prostate cancer intensive, non-cross reactive therapy for CRPâ€"Early observations of efficacy.. Journal of Clinical Oncology, 2020, 38, 89-89.	1.6	1
103	Ocular complications with the use of radium-223: a case series. Radiation Oncology, 2022, 17, 97.	2.7	1
104	The role of hormonal therapy in prostate brachytherapy. Brachytherapy, 2003, 2, 1-2.	0.5	0
105	Prolonged hormonal therapy and external beam radiation independently increase the risk of Persistent Hypogonadism in men treated with prostate brachytherapy. Brachytherapy, 2020, 19, 210-215.	0.5	0
106	Prostate cancer intensive, non-cross reactive therapy (PRINT) for CRPC: Interim analysis of efficacy endpoints.. Journal of Clinical Oncology, 2021, 39, e17027-e17027.	1.6	0
107	Actual total hospital costs of primary localized prostate cancer treatments analyzed by risk group.. Journal of Clinical Oncology, 2012, 30, e15164-e15164.	1.6	0
108	Does race affect the quality of treatment for intermediate-risk and high-risk prostate cancer?. Journal of Clinical Oncology, 2014, 32, e17678-e17678.	1.6	0

#	Article	IF	Citations
109	Radiotherapy versus radical prostatectomy for Gleason score 9-10 prostate adenocarcinoma: A multi-institutional comparative analysis of 1001 patients treated in the modern era.. Journal of Clinical Oncology, 2017, 2017, 7-7.	1.6	0
110	Radiotherapy versus radical prostatectomy for Gleason score 9-10 prostate adenocarcinoma: A multi-institutional comparative analysis of 1001 patients treated in the modern era.. Journal of Clinical Oncology, 2017, 35, 7-7.	1.6	0
111	Clinical outcomes following biochemical recurrence among patients with Gleason score 9-10 prostate adenocarcinoma.. Journal of Clinical Oncology, 2018, 36, 102-102.	1.6	0
112	PRINT: Prostate cancer intensive, non-cross reactive therapy for CRPCâ€"Early observations of feasibility and efficacy.. Journal of Clinical Oncology, 2019, 37, 310-310.	1.6	0
113	Positron emission tomography with 18F-fluciclovine to predict recurrence in post-treatment recurrent prostate cancer and its role in altering treatment plans.. Journal of Clinical Oncology, 2019, 37, 214-214.	1.6	0
114	PRINT: Prostate cancer intensive, non-cross reactive therapy for CRPCâ€"Early observations of efficacy.. Journal of Clinical Oncology, 2020, 38, e17575-e17575.	1.6	0
115	Impact of initial treatment selection on clinical outcomes after biochemical failure in radiorecurrent high-risk prostate cancer.. Journal of Clinical Oncology, 2020, 38, 208-208.	1.6	0
116	Validation of biochemical definition of cure after low-dose rate prostate brachytherapy.. Journal of Clinical Oncology, 2020, 38, 322-322.	1.6	0